Pharma Journalist -

The future of peptide pharmaceuticals is evolving rapidly, with countless positive readouts, new collaborations and groundbreaking innovations in oral delivery in Q1 of 2024 alone.…
Read More...

Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommends CARVYKTI (ciltacabtagene autoleucel, cilta-cel) for…
Read More...

Novartis announced it broke ground for the expansion of its biopharmaceutical manufacturing plant in Singapore. The US$256 million investment will facilitate Novartis in deploying…
Read More...

Almirall, S.A. and Eloxx Pharmaceuticals, Inc. announced that the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement, Almirall obtains…
Read More...

Merck, known as MSD outside of the United States and Canada, at the EUROGIN 2024 HPV Congress, announced plans to initiate clinical development of a new investigational multi-valent HPV…
Read More...

Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for the company’s 20-valent pneumococcal conjugate vaccine, marketed in the European Union…
Read More...

Tierra Biosciences, the company behind the world’s first platform for predictive AI-guided cell-free technology enabling high-throughput on-demand custom protein synthesis, announced…
Read More...

Pearl Bio (a synthetic biology company backed by Khosla Ventures) announced that it has entered a license, collaboration and option agreement with Merck, known as MSD outside of the…
Read More...

Astellas Pharma US, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug and pediatric exclusivity to CRESEMBA (isavuconazonium sulfate) for the…
Read More...

Merck, known as MSD outside of the United States and Canada, announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP). Harpoon is now a wholly-owned…
Read More...